

# Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

## HuCC-T1

RRID:CVCL\_0324

Type: Cell Line

### Proper Citation

RRID:CVCL\_0324

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0324](https://web.expasy.org/cellosaurus/CVCL_0324)

**Proper Citation:** RRID:CVCL\_0324

**Description:** Cell line HuCC-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Intrahepatic cholangiocarcinoma

**Defining Citation:** [PMID:2544546](#), [PMID:9290701](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21451941](#), [PMID:21687941](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26956050](#), [PMID:27231123](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31077409](#), [PMID:31395879](#), [PMID:32899426](#), [PMID:35640676](#), [PMID:35839778](#), [PMID:39026794](#)

**Comments:** Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: Biliary tract cancer cell line atlas.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** HuCC-T1

**Synonyms:** HuCCT-1, HUCCT-1, HUCC-T1, HUCCT1, HuCCT1, HuccT1

**Cross References:** BTO:BTO\_0003911, CLO:CLO\_0050009, MCCL:MCC:0000217, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN01821687, BioSample:SAMN03470954, BioSample:SAMN03471627, BioSample:SAMN10987837, cancercellines:CVCL\_0324, CCRID:5301HUM-KCB21005YJ, Cell\_Model\_Passport:SIDM00587, ChEMBL-Cells:ChEMBL3307409, ChEMBL-Targets:ChEMBL614581, CLS:300469, Cosmic:907069, Cosmic:1122350,

Cosmic:1571782, Cosmic:2009540, Cosmic:2629288, Cosmic:2674063, Cosmic-CLP:907069, DepMap:ACH-000976, EGA:EGAS00001000978, FANTOM5\_SSTAR:10432-106D9, GDSC:907069, GEO:GSM827224, GEO:GSM887144, GEO:GSM888216, GEO:GSM1669917, IARC\_TP53:21387, JCRB:JCRB0425, KCB:KCB 202105YJ, LiGeA:CCLE\_833, LINCS\_LDP:LCL-1788, PharmacDB:HuCC1\_635\_2019, PRIDE:PXD030304, PRIDE:PXD033685, Progenetix:CVCL\_0324, PubChem\_Cell\_line:CVCL\_0324, RCB:RCB1960, TKG:TKG 0389, Wikidata:Q54896725

**ID:** CVCL\_0324

**Record Creation Time:** 20220427T220620+0000

**Record Last Update:** 20260905T180816+0000

---

## Ratings and Alerts

No rating or validation information has been found for HuCC-T1.

No alerts have been found for HuCC-T1.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 375 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#).

Zhou Y, et al. (2026) FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(3), e10782.

Liu Y, et al. (2026) Detection of circulating tumor cells in cholangiocarcinoma via epithelial-mesenchymal transition markers and their application. iScience, 29(4), 115451.

Zhong Y, et al. (2026) HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. iScience, 29(6), 115852.

Li X, et al. (2026) LFPM inhibition of RING1-mediated p53R175H degradation drives oncogenesis in p53R175H-mutant cancers. Cell death and differentiation.

Luo L, et al. (2026) Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti-PD-L1 Efficacy in Intrahepatic Cholangiocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(32), e20403.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. Cancer research communications, 6(3), 616.

Wang F, et al. (2026) MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1. *International journal of biological sciences*, 22(5), 2247.

Cai D, et al. (2026) L-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma. *Cancer letters*, 646, 218394.

Lin Y, et al. (2026) Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. *Cell reports. Medicine*, 7(4), 102708.

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Taguchi D, et al. (2025) Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. *International journal of molecular sciences*, 26(3).

Zhao CH, et al. (2025) Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. *World journal of gastrointestinal oncology*, 17(4), 103776.

Luo G, et al. (2025) Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF- $\beta$ /Smad2 pathway. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(4), 167734.

Inthanachai T, et al. (2025) Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. *Journal for immunotherapy of cancer*, 13(1).

Yuan WC, et al. (2025) HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury. *Cell stem cell*, 32(6), 990.

Myint KZ, et al. (2024) Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. *Pharmaceuticals (Basel, Switzerland)*, 17(2).

Chen T, et al. (2024) S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF- $\kappa$ B/VEGF-D pathway. *Cancer letters*, 587, 216709.

Bekric D, et al. (2024) The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. *PloS one*, 19(4), e0302050.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Noronha KJ, et al. (2024) NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion. *Molecular cancer research : MCR*, 22(10), 973.